Biotech Values

[tony111]

Sorry for SVR I was refering to the seroconversion rate. The trial was to look at the efficacy of combining lamivudine and interferon. The combo is effective in increasing % patients with undetactable HBV DNA, but the seroconversion rate is not significantly different from interferon therapy alone because many patients relapse. I do think interferon lambda has a bigger chance in HBV than HCV because there won't be a direct anti viral cocktail any time soon.